<DOC>
	<DOCNO>NCT00758381</DOCNO>
	<brief_summary>This multicentre , open-label , randomize , phase II trial patient locally advance metastatic pancreatic cancer . Subjects randomized 1:1 ratio receive gemcitabine/cisplatin combination Sorafenib ( arm A ) gemcitabine/cisplatin alone ( arm B ) , first-line chemotherapy .</brief_summary>
	<brief_title>Metastatic Advanced Pancreas Sorafenib</brief_title>
	<detailed_description>Up date standard treatment available pancreatic cancer . Although gemcitabine commonly use patient pancreatic cancer purpose symptom palliation , clear evidence efficacy term survival increase progression control . Furthermore , attempt improve result combine gemcitabine cytotoxic drug fail obtain advantage . Recently , EGFR inhibitor ( erlotinib ) show small survival advantage combine gemcitabine . result obtain combination gemcitabine oxaliplatin seem promise . A meta-analysis randomised trial compare gemcitabine versus gemcitabine platinum analogue show statistical significant survival advantage combination . Sorafenib inhibitor RAS/RAF signal pathway . Furthermore , sorafenib able inhibit VEGFR PDGFR . Since RAS RAF mutation quite common pancreatic cancer , Sorafenib could useful management tumour . Furthermore , may combine gemcitabine cisplatin without pharmacokinetic interaction enhance toxicity .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Signed write informed consent prior begin protocol specific procedure Male female 18 75 year age Diagnosis histologically confirm adenocarcinoma pancreas Locally advance ( nonresectable ) metastatic pancreatic cancer Presence least one unidimensional indicator lesion measurable CT scan MRI irradiate area ( RECIST criterion ) Karnofsky performance status ≥ 70 study entry Neutrophils ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , hemoglobin ≥ 9 g/dL Bilirubin level either normal &lt; 1.5 x ULN ASAT ALAT ≤ 2.5 X ULN ( ≤ 5 x ULN liver metastasis present ) Serum creatinine &lt; 1.5 x ULN Amylase lipase ≤ 1.5 x upper limit normal PT INR PTT &lt; 1.5 x upper limit normal ( subject receive anticoagulation treatment agent warfarin heparin allow participate provide evidence underlying abnormality parameter exist ) . Effective contraception male female patient risk conception exists Brain metastasis Previous chemotherapy locally advance metastatic pancreatic cancer . Adjuvant therapy document recurrence within 6 month end adjuvant treatment ) Radiotherapy within 4 week prior study entry Major surgery within 4 week first dose study drug Concurrent chronic systemic immune therapy Any investigational agent ( ) 4 week prior entry Clinically relevant coronary artery disease history myocardial infarction within last 6 month Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Acute subacute intestinal occlusion history inflammatory bowel disease Known grade 3 4 allergic reaction component treatment Known drug abuse/ alcohol abuse Legal incapacity limit legal capacity Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent Women pregnant breastfeed Acute subacute intestinal occlusion Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Patients previous malignancy without evidence disease ≥ 5 year allow enter trial ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>advanced metastatic</keyword>
	<keyword>sorafenib</keyword>
</DOC>